证券代码：603665 证券简称：康隆达 公告编号：2025-032 浙江康隆达特种防护科技股份有限公司（以下简称"公司"或"康隆达"）第五届董事会第十三次会议通知 于2025年5月9日以电话、传真、电子邮件等形式发出，会议于2025年5月13日以现场结合通讯表决方式 在公司会议室召开。会议应出席董事5名，实际出席董事5名。本次会议由董事长张家地先生主持，公司 监事及部分高级管理人员列席了会议。本次会议的召集、召开及表决程序符合《中华人民共和国公司 法》等法律、行政法规、部门规章、规范性文件和《公司章程》的规定，会议决议合法有效。 二、董事会会议审议情况 （一）审议通过《关于使用部分闲置募集资金暂时补充流动资金的议案》 在保证募集资金投资项目建设的资金需求的前提下，公司拟使用不超过（含）人民币5,500万元的闲置 募集资金暂时补充流动资金，使用期限自公司董事会审议批准之日起不超过12个月。 表决结果：5票同意、0票反对、0票弃权。 浙江康隆达特种防护科技股份有限公司 第五届董事会第十三次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和 ...

Core Viewpoint - The supervisory board of Hualan Biological Engineering Co., Ltd. held its 15th meeting of the 8th session, approving several key proposals including the annual report, profit distribution plan, and changes in accounting policies, all of which will be submitted for shareholder approval at the upcoming annual general meeting [1][2][3]. Meeting Overview - The meeting was held on March 28, 2025, with all three supervisory board members present, complying with legal and regulatory requirements [1]. Resolutions Passed - The supervisory board approved the 2024 Annual Work Report, which will be submitted for shareholder review [2]. - The 2024 Annual Report and its summary were also approved, confirming that the report accurately reflects the company's situation without any misleading statements [2]. - The 2024 Financial Settlement Report was approved, pending shareholder approval [2]. - A profit distribution plan was approved, proposing a cash dividend of 2 yuan per 10 shares, totaling approximately 365.76 million yuan, with remaining undistributed profits rolling over to the next year [2][3]. - Changes to accounting policies and estimates were approved, ensuring compliance with the latest accounting standards without significantly impacting the company's financial status [3][4]. - The 2024 Internal Control Self-Evaluation Report was approved, indicating a robust internal control system in place [4]. - The proposal to use idle funds for investment and financial management was approved, aimed at improving fund utilization efficiency [5]. - The reappointment of the auditing firm for 2025 was approved, pending shareholder approval [5]. - The proposal to repurchase and cancel certain restricted stock options from the 2023 incentive plan was approved, ensuring compliance with relevant regulations [6]. - A proposal to amend the company's registered capital and related articles in the Articles of Association was approved, pending shareholder approval [6][7]. - The establishment of a Public Opinion Management System and a Market Value Management System was approved [7].